These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 37545724)

  • 1. Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders.
    Takai Y; Misu T; Fujihara K; Aoki M
    Front Neurol; 2023; 14():1209749. PubMed ID: 37545724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
    Höftberger R; Guo Y; Flanagan EP; Lopez-Chiriboga AS; Endmayr V; Hochmeister S; Joldic D; Pittock SJ; Tillema JM; Gorman M; Lassmann H; Lucchinetti CF
    Acta Neuropathol; 2020 May; 139(5):875-892. PubMed ID: 32048003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
    Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease.
    Corbali O; Chitnis T
    Front Neurol; 2023; 14():1137998. PubMed ID: 36925938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
    Jarius S; Ringelstein M; Schanda K; Ruprecht K; Korporal-Kuhnke M; Viehöver A; Hümmert MW; Schindler P; Endmayr V; Gastaldi M; Trebst C; Franciotta D; Aktas O; Höftberger R; Haas J; Komorowski L; Paul F; Reindl M; Wildemann B
    J Neurol; 2024 Jul; 271(7):4660-4671. PubMed ID: 38609667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.
    Sechi E; Cacciaguerra L; Chen JJ; Mariotto S; Fadda G; Dinoto A; Lopez-Chiriboga AS; Pittock SJ; Flanagan EP
    Front Neurol; 2022; 13():885218. PubMed ID: 35785363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Lopez JA; Denkova M; Ramanathan S; Dale RC; Brilot F
    Clin Transl Immunology; 2021; 10(7):e1316. PubMed ID: 34336206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of demographic, clinical and imaging features of myelin oligodendrocyte glycoprotein antibody positive, aquaporin 4 antibody positive, and double seronegative demyelinating disorders - An Indian tertiary care center prospective study.
    Salunkhe M; Gupta P; Singh RK; Elavarasi A; Vibha D; Garg A; Bhatia R; Tripathi M
    J Neurosci Rural Pract; 2023; 14(2):313-319. PubMed ID: 37181191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MOG CNS Autoimmunity and MOGAD.
    Moseley CE; Virupakshaiah A; Forsthuber TG; Steinman L; Waubant E; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200275. PubMed ID: 38996203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.